Management of Elevated Urine Microalbumin to Creatinine Ratio

Diagnostic Criteria and Screening

Microalbuminuria is defined as urinary albumin excretion of 30-299 mg/24h, equivalent to 30-299 mg/g creatinine on a random spot urine sample, according to the American Diabetes Association 4, 5
Diagnosis requires confirmation with 2 out of 3 abnormal specimens collected within a 3-6 month period due to variability in urinary albumin excretion, as recommended by the American Diabetes Association 6, 3
First morning void samples are preferred to minimize the effect of orthostatic proteinuria, which is common in adolescents, as suggested by the American Academy of Pediatrics 1, 7
Several factors can cause transient elevations in urinary albumin excretion: exercise within 24h, infection, fever, heart failure, marked hyperglycemia, hypertension, menstruation, and hematuria, according to the American Diabetes Association 4, 6, 3

For patients with microalbuminuria (30-299 mg/g creatinine), the American Diabetes Association recommends starting ACE inhibitor or ARB therapy even if blood pressure is normal 2, 3
The American Academy of Pediatrics suggests titrating medication to normalize microalbumin excretion if possible 1, 7
The American Diabetes Association recommends monitoring serum creatinine and potassium levels regularly after starting therapy 2, 3
For patients with macroalbuminuria (≥300 mg/g creatinine) and/or eGFR <60 mL/min/1.73 m², the American Diabetes Association strongly recommends ACE inhibitor or ARB therapy 2, 3

The American Diabetes Association recommends optimizing glycemic control to reduce risk or slow progression of diabetic kidney disease 2, 9
The American Academy of Pediatrics suggests optimizing blood pressure control (<130/80 mmHg) 1, 9
The American Diabetes Association recommends implementing dietary modifications, including protein intake of approximately 0.8 g/kg body weight per day 2, 9

The American Academy of Pediatrics recommends monitoring microalbumin excretion every 3-6 months to assess response to therapy 1, 7
The American Diabetes Association suggests annual screening of eGFR 3, 9
The American College of Physicians recommends increasing the frequency of monitoring with disease severity according to GFR and albuminuria categories 8

The American Diabetes Association advises caution with ACE inhibitors/ARBs, as they may cause acute kidney injury in patients with bilateral renal artery stenosis or advanced renal disease 4, 5
The American College of Obstetricians and Gynecologists notes that ACE inhibitors and ARBs are contraindicated in pregnancy 4
The American Diabetes Association recommends considering referral to nephrology when there is uncertainty about etiology, difficult management issues, rapidly progressing kidney disease, or eGFR <30 mL/min/1.73 m² 2, 3

The European Society of Cardiology notes that microalbuminuria predicts increased risk for cardiovascular events and mortality, independent of other risk factors 10